Radioimmunotherapy

This is a type of cancer treatment that uses radiation linked to antibodies. The goal is to target cancer cells directly with radiation, potentially harming nearby cells less.

Procedure

What people who've had Radioimmunotherapy report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Radioimmunotherapy

Who It's For

Radioimmunotherapy is a cancer treatment that attaches a radioactive substance to an antibody, a lab-made protein designed to lock onto a specific marker on cancer cells. The antibody carries the radiation through the bloodstream to wherever the cancer is, and the radiation damages the cancer cells it binds to as well as nearby cancer cells the antibody did not reach. Unlike external radiation, which is aimed at one area from outside the body, it can reach disease spread across many lymph nodes. In the US, the radioimmunotherapy in clinical use is ibritumomab tiuxetan (Zevalin), carrying the radioactive element yttrium-90. It targets CD20, a protein marker found on most B-cell non-Hodgkin lymphomas. It is approved for adults with follicular or other low-grade B-cell lymphoma that has come back or stopped responding to treatment, and for adults with newly diagnosed follicular lymphoma whose disease shrank with first chemotherapy, as a one-time follow-up treatment. A second similar drug, tositumomab (Bexxar), is no longer marketed in the US. Other targets and other cancers are being studied, but only in clinical trials. In studies, a single course often shrank lymphoma and, after first chemotherapy, roughly doubled the time before the lymphoma grew back (a median of about 3 years compared with 1.5 years with no further treatment). It has not been shown to help people live longer. Since it was approved, other options such as rituximab maintenance infusions and newer targeted drugs have become more common, and radioimmunotherapy is now offered at relatively few centers because it needs a team that includes blood cancer specialists and nuclear medicine and radiation-safety staff. Whether it suits someone depends on the lymphoma type, how much is in the bone marrow, blood counts and earlier treatment.

Before the Procedure

Because the main side effect is a drop in blood counts, eligibility centers on the bone marrow, where blood cells are made. Blood counts are checked, and a bone marrow biopsy shows how much lymphoma is in the marrow. Treatment is not given if lymphoma makes up 25% or more of the marrow or if the marrow is already weakened, for example by heavy earlier chemotherapy. After first chemotherapy, treatment usually starts 6 to 12 weeks after the last dose, once platelets (the cells that help blood clot) have recovered to normal levels. The team also reviews kidney and liver tests and any earlier radiation. The radiation can harm a developing baby, so pregnancy is ruled out first. Women who could become pregnant, and men with partners who could, should use effective birth control during treatment and for at least 12 months afterward. Breastfeeding should stop and not restart for 6 months. Tell the team about all medicines and supplements, especially blood thinners and anything that affects clotting or platelets, since bleeding becomes a concern when platelet counts fall. The care team gives specific instructions on what to continue or pause.

During the Procedure

Treatment is usually done as an outpatient over two visits about a week apart. On the first day, you receive an infusion of rituximab, a non-radioactive antibody against the same CD20 marker, through an IV (a thin tube placed in a vein). Rituximab first occupies many of the normal B cells in the blood and spleen, which helps the radioactive dose that follows concentrate in the lymphoma. Acetaminophen and the antihistamine diphenhydramine are given beforehand to reduce infusion reactions. The first rituximab infusion starts slowly and is sped up only if it is well tolerated. On day 7, 8 or 9, you get a second rituximab infusion, followed within 4 hours by the radioactive Zevalin itself, which runs into the vein over about 10 minutes. The dose is calculated from body weight and platelet count. You do not feel the radiation. Staff watch the IV site closely, because radioactive fluid leaking into the surrounding tissue can damage it, and they restart the infusion in another arm if this happens. Rituximab infusions can cause reactions such as chills, fever, hives, low blood pressure or trouble breathing, usually within the first one to two hours of the first infusion. They are occasionally severe, which is why treatment is given only where staff can respond immediately. Tell the nurse at once about any new symptom during an infusion.

Recovery & Aftercare

Most people go home the same day and can return to usual activities. Fatigue, nausea, mild abdominal pain, cough, cold-like symptoms and low-grade fever are common in the following weeks. Yttrium-90 gives off radiation that travels only a short distance, so special shielding at home is generally not needed. Some product guidance advises washing hands well after using the toilet and using condoms for 7 days to avoid passing on body fluids. Follow the specific instructions your center gives. The effect on blood counts is delayed. Platelets and white blood cells usually fall to their lowest point about 7 to 9 weeks after treatment and often stay low for several weeks before recovering. Blood counts are checked weekly until they recover, and the risk of infection and bleeding remains for up to 3 months. Some people need a platelet or red cell transfusion or medicine to boost white cells. During this time, avoid medicines that affect platelets unless your care team approves them. Call your care team right away for a fever or other signs of infection, or for unusual bleeding, easy bruising, tiny red or purple spots on the skin, or new paleness, weakness or unusual tiredness. Live vaccines are not recommended for 12 months after treatment. Follow-up with blood tests continues for years because some effects appear late.

Risks & Complications

The most important risk is prolonged, severe lowering of blood counts, which happens in most people. Low platelets increase the risk of bleeding, and low white cells increase the risk of serious infection. The risk is greater when the marrow already has some damage or platelets start slightly low, which is why eligibility rules are strict. The rituximab part of the treatment can cause serious infusion reactions, rarely fatal, mostly with the first infusion. Rarely, severe skin and mouth reactions, including blistering and peeling of the skin or sores and peeling inside the mouth, have occurred anywhere from a few days to 4 months after treatment. A widespread rash, blisters or peeling skin or mouth needs medical evaluation the same day. Later, the radiation raises the risk of second cancers, especially myelodysplastic syndrome (a disorder in which the marrow makes faulty blood cells) and acute myeloid leukemia. In the main trial after first chemotherapy, these marrow cancers developed in about 3% of treated people over roughly 7 years, compared with under 1% of people who had no further treatment, and the risk can appear years later. This long-term risk is part of why many doctors now prefer other follow-up treatments for newly diagnosed follicular lymphoma. The treatment can harm a pregnancy, which is why birth control is needed for at least a year. Radioimmunotherapy is designed as a single course, and the lymphoma often returns eventually, so further treatment may be needed.

Questions to Ask Your Doctor

  1. 1.Why are you recommending radioimmunotherapy for my lymphoma instead of rituximab maintenance, other targeted drugs or more chemotherapy?
  2. 2.Does my bone marrow biopsy and blood count make me a good candidate, and how low are my counts likely to go?
  3. 3.How would this treatment affect my options if I later need a stem cell transplant, immune cell therapy such as CAR T-cell therapy, or other treatment?
  4. 4.What is my risk of a later leukemia or other second cancer, and how will you monitor for it?
  5. 5.Which medicines should I avoid while my platelets are low, and who should I call with a fever after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.